Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Trial of Chemotherapy With or Without Panitumumab in Metastatic/Recurrent Squamous Cell Carcinoma of the Head and Neck
2006-003786-13Phase 3Completed
- Sponsor
- Amgen
- Start
- Feb 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of panitumumab in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Amgen. Primary endpoint: Overall survival. Started Feb 2007; status: completed.
02
Drugs
panitumumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2006-003786-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003786-13.